Promising New Oral Drug for Ulcerative Colitis Shows Landmark Success in Late-Stage Trials

Published: June 2, 2026 | 5:19 AM IST

PARIS — Paris-based biotechnology company Abivax announced Monday that its experimental oral drug, obefazimod, successfully met its primary endpoint in a critical late-stage Phase 3 clinical trial for the treatment of ulcerative colitis. This chronic, painful inflammatory bowel disease (IBD) affects millions of individuals globally, many of whom exhaust existing therapeutic options without achieving lasting relief. The positive results from the ABTECT maintenance trial represent a potential paradigm shift, offering a highly effective, once-daily oral alternative for individuals living with moderate-to-severe forms of the condition.

Landmark Efficacy in Phase 3 Maintenance Trials

The Phase 3 ABTECT maintenance trial evaluated the long-term efficacy and safety of obefazimod in individuals with moderate-to-severe ulcerative colitis. The trial demonstrated remarkable results, with both evaluated doses achieving clinical remission in over half of the study participants by Week 44.

Specifically, clinical remission rates reached 50.8% for the 25 mg dose and 51.3% for the 50 mg dose. In stark contrast, only 10.4% of participants in the placebo group achieved remission. The placebo-adjusted clinical remission rates stood at 39.3% for the 25 mg cohort and 40.3% for the 50 mg cohort—results that carry immense statistical significance ($p < 0.0001$). Abivax has characterized these outcomes as “best-in-disease” placebo-adjusted remission rates compared to currently approved advanced ulcerative colitis therapies.

Beyond the primary endpoint, the drug met all key secondary endpoints at Week 44, including:

• Endoscopic improvement and full endoscopic remission (healing of the colon lining)

• Histological endoscopic mucosal improvement (HEMI), indicating cellular-level healing

• Sustained clinical remission

• Corticosteroid-free clinical remission

The placebo-adjusted rates across these rigorous secondary outcomes ranged from 31.4% to 52.8%, underscoring a deep, structural healing of the gastrointestinal tract rather than temporary symptom management.

The Growing Global Burden of Ulcerative Colitis

Ulcerative colitis is a chronic, immune-mediated inflammatory condition affecting the innermost lining of the large intestine (colon) and rectum. It is characterized by unpredictable periods of grueling flare-ups—featuring severe abdominal pain, bloody stool, fatigue, and an urgent need to defecate—interspersed with periods of remission.

The development of novel treatments arrives at a critical juncture. The global footprint of inflammatory bowel disease (which encompasses both ulcerative colitis and Crohn’s disease) is expanding rapidly. Recent epidemiological data indicates that the global prevalence of IBD rose from 0.22% in 1990 to 1.6% in 2022, with ulcerative colitis driving the vast majority of this increase, climbing from 0.16% to 1.12%.

Historically concentrated in highly industrialized nations, the burden remains exceptionally high in these regions. Europe reports the highest overall prevalence, with roughly 348.4 per 100,000 people living with IBD, and ulcerative colitis specifically accounting for 198.6 per 100,000. In the United States, where the incidence is reported at 378 per 100,000 person-years, more than 1 million residents live with the condition, alongside 2.5 million individuals in Europe. However, newly industrialized countries across Asia, South America, and the Middle East are experiencing steep escalations in diagnoses, transforming IBD into a global health crisis.

While current medical options include anti-inflammatory aminosalicyclates, systemic immunosuppressants, injectable biologic therapies (such as TNF-inhibitors), and oral small molecules, a massive therapeutic gap remains. A substantial percentage of patients fail to respond to initial therapy—a phenomenon known as primary non-response—or lose responsiveness over time, frequently leaving surgical removal of the colon as the only remaining option.

A First-in-Class Mechanism: How Obefazimod Works

Obefazimod (previously designated as ABX464) is a first-in-class, oral small molecule that introduces an entirely unique therapeutic mechanism. Unlike conventional biologic therapies or JAK inhibitors, which typically target and block specific pro-inflammatory proteins or cytokines in the immune cascade, obefazimod selectively enhances the expression of miR-124.

MicroRNA-124 (miR-124) is a naturally occurring single micro-RNA that acts as a master physiological regulator of the inflammatory response. By upregulating this micro-RNA, obefazimod effectively “turns down the volume” on the immune system’s overactive inflammatory pathways, downregulating multiple inflammatory cytokines simultaneously.

Crucially, the drug is formulated as a convenient, once-daily oral pill taken with food in the morning. This provides a significant quality-of-life advantage over existing advanced therapies, many of which require regular, disruptive intravenous infusions or subcutaneous injections.

Building on Early Induction Success

The definitive maintenance data builds directly upon the success of Abivax’s twin Phase 3 induction trials, ABTECT-1 and ABTECT-2. These initial trials comprised a massive global program, enrolling 1,275 patients across more than 600 clinical sites worldwide.

In the induction data released in July 2025, the 50 mg dose achieved placebo-adjusted clinical remission rates of 19.3% in ABTECT-1 and 13.4% in ABTECT-2 at Week 8. While the lower 25 mg dose met its primary endpoint in the first induction trial but missed statistical significance in the second, its powerful performance in the newly completed 44-week maintenance trial suggests that longer-term exposure allows the lower dose to achieve maximum therapeutic efficacy.

“The strength of these results reinforces our belief in obefazimod, our first-in-class miR-124 enhancer, and its potential to become a transformative new treatment modality for patients with UC,” stated Marc de Garidel, CEO of Abivax, during an industry address.

Safety and Long-Term Tolerability

In chronic diseases requiring lifelong management, a drug’s long-term safety profile is just as vital as its efficacy. According to Abivax, the safety profile observed in the ABTECT maintenance trial aligned consistently with prior clinical registry data.

Long-term safety evaluation from an earlier Phase 2b open-label extension study tracked patients out to 96 weeks. The most frequent treatment-emergent adverse events identified included:

• COVID-19 infection (14.3%)

• Headache (11.5%)

• Worsening or flare of ulcerative colitis (7.8%)

• Nasopharyngitis (6.9%)

Importantly, no new or unexpected safety signals emerged over the prolonged 96-week window, supporting a stable safety profile for the 50 mg once-daily regimen. Furthermore, extended data revealed that 68% of patients who transitioned into the long-term open-label study remained in stable clinical remission at Week 144, indicating that the drug’s efficacy does not rapidly diminish over time.

Independent Expert Commentary & Market Disruptions

The gastroenterology community has reacted with cautious optimism to the latest data. Independent experts note that while cross-trial comparisons are inherently difficult, a placebo-adjusted remission rate hovering around 40% in a maintenance trial is highly competitive.

Particularly significant is the achievement of corticosteroid-free remission. Prolonged use of corticosteroids (such as prednisone) to control flares is notoriously hazardous, carrying severe long-term side effects including bone density loss (osteoporosis), heightened infection susceptibility, cataracts, and metabolic disruptions like weight gain and diabetes. Delivering a therapeutic option that allows patients to safely stop steroids while maintaining clinical remission is a critical clinical achievement.

The pharmaceutical industry has reacted intensely to obefazimod’s clinical trajectory. Following the initial induction trial success in July 2025, Abivax’s stock experienced a dramatic 500% surge in a single trading day on the Paris exchange, climbing from €8.90 to roughly €56, and ultimately posting a massive 1,600% gain over the course of that year. This momentum has made the biotech firm a prime target for industry consolidation, prompting widespread market rumors of a potential $17.5 billion acquisition bid by pharmaceutical giant Eli Lilly, though corporate leadership has consistently dismissed the reports as external market speculation.

Real-World Considerations and Study Limitations

Despite the highly encouraging clinical trial findings, medical experts emphasize that several crucial caveats must be carefully considered before obefazimod can be fully integrated into standard clinical practice:

• Establishing Extended Safety: While data out to 144 weeks is highly encouraging, tracking safety and potential rare side effects over decades of real-world use remains an ongoing necessity.

• The “Clinical Trial” Disconnect: Clinical trial populations are highly controlled and typically exclude individuals with severe, complex comorbidities (such as advanced cardiovascular disease or concurrent auto-immune disorders). Real-world efficacy and safety profiles can fluctuate once a drug is prescribed to a broader, less homogeneous population.

• The Lack of Head-to-Head Data: Abivax has not conducted direct, head-to-head clinical trials comparing obefazimod against existing advanced oral therapies (like upadacitinib or ozanimod). Without these direct comparisons, clinicians cannot definitively state which drug is superior for specific patient profiles.

• Patient Accessibility and Cost: Innovative, first-in-class specialized therapies entering the IBD market routinely carry substantial price tags. High out-of-pocket costs or restrictive insurance coverage could severely limit access for the very patients who require the medication most.

Next Steps and Regulatory Timeline

With the successful completion of the Phase 3 ABTECT maintenance trial, Abivax is actively compiling its regulatory portfolios. The company announced plans to formally submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026. Parallel regulatory submissions are planned for the European Medicines Agency (EMA) shortly thereafter.

If the regulatory review process proceeds smoothly and without unforeseen administrative or manufacturing delays, obefazimod could secure regulatory approval and become commercially available to eligible patients within the next 12 to 18 months.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.reuters.com/business/healthcare-pharmaceuticals/abivaxs-inflammatory-bowel-drug-meets-main-goal-late-stage-trial-2026-06-01/